email print share on facebook share on twitter share on google+


Romanian hospital drama Biocide now in post-production


- The debut feature by Gabi Virginia Şarga and Cătălin Rotaru is being produced by Axis Media Production and Green Cat Film

Romanian hospital drama Biocide now in post-production
Alexandru Suciu in Biocide

Two years after their very first short film, 4.15 PM The End of the World, was selected in the short-film competition at the Cannes Film Festival, directors Gabi Virginia Şarga and Cătălin Rotaru are currently in post-production with their first feature, Biocide. The project is being produced by Axis Media Production, founded by Adina Sădeanu, and co-produced by Green Cat Film, founded by the two directors. 

(The article continues below - Commercial information)

The screenplay, written by Şarga and Rotaru, follows Cristian (Alexandru Suciu), a young surgeon who is deeply upset after one of his patients dies following successful surgery. Convinced that the patient died because of a bacterial infection caused by poor hospital sanitation, Cristian will become the protagonist of a David versus Goliath conflict with the management. Other important characters are played by Cristina FluturGelu ColceagTania FilipElias Ferkin and Daniel Popa

The film was shot over 21 days in November, in Bucharest and the surrounding areas, with Tudor Platon serving as DoP. The budget amounts to approximately €310,000, with circa €100,000 coming from the Romanian National Film Center.

Asked if the story is inspired by personal experiences, Cătălin Rotaru says Biocide is “a fiction, but a very personal fiction”. As for Gabi Virginia Şarga, she says, “At first glance, the film is about the healthcare system, but it actually tackles the corruption present in various areas of society, by showing the Don Quixotesque fight of a man who will be a hero for five minutes.” 

Post-production is expected to wrap in the spring, with a domestic release tentatively planned for the second part of the year.

Did you enjoy reading this article? Please subscribe to our newsletter to receive more stories like this directly in your inbox.